Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial

@article{Volc2020SafetyAI,
  title={Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial},
  author={D. Volc and W. Poewe and A. Kutzelnigg and R. Medori},
  journal={The Lancet Neurology},
  year={2020},
  volume={19},
  pages={591-600}
}
  • D. Volc, W. Poewe, +1 author R. Medori
  • Published 2020
  • Medicine
  • The Lancet Neurology
  • BACKGROUND Robust evidence supports the role of α-synuclein pathology as a driver of neuronal dysfunction in Parkinson's disease. PD01A is a specific active immunotherapy with a short peptide formulation targeted against oligomeric α-synuclein. This phase 1 study assessed the safety and tolerability of the PD01A immunotherapeutic in patients with Parkinson's disease. METHODS We did a first-in-human, randomised, phase 1 study of immunisations with PD01A, followed by three consecutive study… CONTINUE READING
    8 Citations
    "Eine Impfung wäre viel praktischer als die Infusion von Antikörpern"
    • T. Müller
    • Medicine
    • InFo Neurologie + Psychiatrie
    • 2020
    Immunotherapy for Parkinson's disease: stay tuned

    References

    SHOWING 1-10 OF 24 REFERENCES
    Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.
    • 98
    Therapeutic approaches to target alpha-synuclein pathology
    • 99
    Controlling the mass action of α‐synuclein in Parkinson’s disease
    • 76